Search research articles
Contact Us
Filters
Showing results (821-830 of 869) with videos related to
Page
of 87
Sort By:
Virus Evolution
|
September 17, 2021
RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection
Eric Lewitus, Eric Sanders-Buell, Meera Bose, et al.
Nature Communications
|
January 19, 2023
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
Youyi Fong, Yunda Huang, David Benkeser, et al.
Nature Communications
|
March 23, 2023
Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
Youyi Fong, Yunda Huang, David Benkeser, et al.
Plos Computational Biology
|
February 4, 2015
Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial
Paul T Edlefsen, Morgane Rolland, Tomer Hertz, et al.
NPJ Vaccines
|
March 10, 2023
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
David Benkeser, Youyi Fong, Holly E Janes, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 19, 2024
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features
Michal Juraska, Hongjun Bai, Allan C deCamp, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 17, 2021
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
Peter B Gilbert, David C Montefiori, Adrian McDermott, et al.
Science (New York, N.Y.)
|
November 23, 2021
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Peter B Gilbert, David C Montefiori, Adrian B McDermott, et al.
NPJ Vaccines
|
May 3, 2026
Searching for immune correlates in Lassa vaccine development - workshop report
Trevor Brasel, Polina Brangel, Ifedayo Adetifa, et al.
Emerging Microbes & Infections
|
April 7, 2025
A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials
Zoe Moodie, Shuying Sue Li, Elena E Giorgi, et al.
Page
of 87
Search research articles
Search
Showing results (821-830 of 869) with videos related to
Sort By:
Page
of 87
Virus Evolution
|
September 17, 2021
RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection
Eric Lewitus, Eric Sanders-Buell, Meera Bose, et al.
Nature Communications
|
January 19, 2023
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
Youyi Fong, Yunda Huang, David Benkeser, et al.
Nature Communications
|
March 23, 2023
Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
Youyi Fong, Yunda Huang, David Benkeser, et al.
Plos Computational Biology
|
February 4, 2015
Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial
Paul T Edlefsen, Morgane Rolland, Tomer Hertz, et al.
NPJ Vaccines
|
March 10, 2023
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
David Benkeser, Youyi Fong, Holly E Janes, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 19, 2024
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features
Michal Juraska, Hongjun Bai, Allan C deCamp, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 17, 2021
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
Peter B Gilbert, David C Montefiori, Adrian McDermott, et al.
Science (New York, N.Y.)
|
November 23, 2021
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Peter B Gilbert, David C Montefiori, Adrian B McDermott, et al.
NPJ Vaccines
|
May 3, 2026
Searching for immune correlates in Lassa vaccine development - workshop report
Trevor Brasel, Polina Brangel, Ifedayo Adetifa, et al.
Emerging Microbes & Infections
|
April 7, 2025
A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials
Zoe Moodie, Shuying Sue Li, Elena E Giorgi, et al.
Page
of 87